Mumps

Mumps is a viral contagious disease caused by the mumps virus (MuV) that mainly affects the glands, leading to their inflammation and swelling. Our company is poised to help our customers propel the groundbreaking mumps vaccine and mumps therapeutics developments due to our vast experience and modern facilities.

Introduction to Mumps

Mumps is an infectious disease caused by the mumps virus which comes from the Paramyxoviridae family. Mumps often starts off with fever, a headache and parotitis (swelling of salivary glands) and can have serious complications like meningitis and orchitis, and in rare cases can lead to deafness. Before a vaccine was developed, mumps commonly afflicted children and outbreaks within communities were normal.

Fig.1 Mumps cases in 2017 and ongoing. (Bockelman C., et al., 2018)

Vaccine Development for Mumps

• Monovalent Mumps Vaccines
  The first focus for vaccinologists was the development of a single agent mumps vaccine. These were the initial vaccines developed for mumps and made the disease the most easily preventable childhood illness.
• Measles-Mumps-Rubella (MMR) Vaccines
  The introduction of combination vaccines, including the MMR vaccine, was a great leap forward. It was possible to reduce the rate of all three diseases by combining the mumps vaccine with measles and rubella vaccines because immunization campaigns could be simplified.
• Measles-Mumps-Rubella-Varicella (MMRV) Vaccines
  As science became more advanced, modern medicine invented the tetravalent MMRV vaccine, which offers protection from four diseases: Measles, Mumps, Rubella and Varicella (chicken pox). This vaccination is more effective in areas where chicken pox is also a health concern.

Table 1 List of mumps vaccine strains and corresponding genotypes. (Almansour I., 2020)

Therapeutics Development for Mumps

Scientists are interested in the use of antiviral medication to treat a Paramyxovirus infection. Some of the new ways of targeting viruses include:

• Nucleoside Analogs: These medications could work by blocking virus replication through targeting viral RNA.
• Viral Entry Inhibitors: Blocking viral entry into a host cell prevents the start of infection.
• Interferon-based Therapies: Amplifying the body's natural interferon response could augment the immune response to a viral infection.

Our Services

The continuously evolving mumps vaccine and therapeutic innovations are supported by our intelligent team of scientists and researchers with the help of state-of-the-art biotechnology along with useful development processes. Through our services, the clients are able to harness the vast experience and resources needed to foster progress in this important area.

Vaccine Development

• Live-attenuated Vaccine
• Inactivated Vaccine
• Toxoid Vaccine
• Viral Vector Vaccine
• Virus-like Particles Vaccine
• Protein Subunit Vaccine
• mRNA Vaccine
• DNA Vaccine

Therapeutic Development

• Small Molecule Drug Development Services
• Therapeutic mRNA Development Services
• Therapeutic Antibody Development Services
• Cell Therapy Development Services

Disease Models

• Type I Interferon (IFN) alpha/beta Receptor Knockout Mice (IFN-α/βR−/−) Models
• MuV Infection Wild-type C57BL/6 Mice Models
• MuV Infection Ferrets Models
• MuV Infection Rhesus Macaques Models

Preclinical research is a critical phase in the development of any new vaccine or therapy. Our services in this area include:

• Molecular Characterization: Detailed analysis of the mumps virus to identify potential targets for vaccine and drug development.
• Immunogenicity Studies: Assessing the immune response to candidate vaccines to ensure they can elicit a protective immune response.
• Efficacy Testing: Rigorous testing in controlled laboratory environments to evaluate the efficacy of new vaccines and therapies before they proceed to clinical trials.

If you are interested in our services, please feel free to contact us.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.